Copaxone is indeed a lot less effective but on the other hand quite safe, and unfortunately as long as there is no cure for MS, even weaker agents will still have a decent place in treatment arsenal, although will defiantly lose market share.
Recall DEFINE Data showed 94% reduction in the mean number of gadolinium enhancing lesions over 2 years compared to placebo, and by 74% in the CONFRIM study. So I hope and wish your wife the very best effect with Tecfidera. A question if it's ok with you: after the initial blood work and while on the drug, how often should your wife be checked for lymphopenia? I'm asking because I would be testing more often than once a year as the FDA guided, in JCV+ Tysabri switchers.
Market Data 
Markets 
AI
